China Health Industries Holdings SG&A Expenses 2016-2024 | CHHE

China Health Industries Holdings sg&a expenses from 2016 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

China Health Industries Holdings SG&A Expenses 2016-2024 | CHHE

China Health Industries Holdings sg&a expenses from 2016 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.6B
Vertex Pharmaceuticals (VRTX)$117.1B
Regeneron Pharmaceuticals (REGN)$111.8B
Bristol Myers Squibb (BMY)$109.9B
Gilead Sciences (GILD)$104.8B
CSL (CSLLY)$95.8B
GSK (GSK)$79.5B
Alnylam Pharmaceuticals (ALNY)$34.6B
Argenex SE (ARGX)$32.5B
BioNTech SE (BNTX)$28.5B
Biogen (BIIB)$26.9B
Moderna (MRNA)$23.5B
BeiGene (BGNE)$22.7B
Illumina (ILMN)$21.7B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$12.9B
Incyte (INCY)$12.9B
Vaxcyte (PCVX)$12.4B
Exact Sciences (EXAS)$12.3B
Insmed (INSM)$12.3B
Bio-Techne Corp (TECH)$11.7B
Sarepta Therapeutics (SRPT)$11.3B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.7B
Roivant Sciences (ROIV)$8.3B
Ascendis Pharma (ASND)$8.2B
Repligen (RGEN)$7.8B
Revolution Medicines (RVMD)$7.7B
Halozyme Therapeutics (HALO)$7.7B